Afya reports Q3 adjusted EBITDA R$398.9M, up 14.6% y/y

Reports Q3 revenue R$928.5M, or R$926.2M excluding acquisitions, vs. R$841.2M last year. Company management stated: “This quarter demonstrates once again Afya‘s (AFYA) ability to combine transformation with financial discipline. We advanced in initiatives that strengthen our ecosystem, and accelerate innovation, while maintaining a prudent approach to capital allocation. These achievements reinforce our confidence in the strategy and our capacity to deliver sustainable growth and long-term value for all stakeholders. We saw steady advances across our three segments, reflecting our commitment to integrate education and medical practice solutions throughout the medical journey. In Undergraduate, we concluded another intake cycle, ensuring full occupancy across all our medical schools, which reinforces Afya’s differentials and the ability to attract and retain top candidates nationwide. This approach ensures consistency in admissions, strengthens our brand positioning, and optimizes operational efficiency. In Continuing Education, we sustained impressive growth in B2B Revenue, while strengthening the graduate journey. In Medical Practice Solutions we achieved a notable increase in active payers within Clinical Management, reinforcing the value of our solutions in supporting physicians’ daily practice. Our ecosystem continues to enhance learning outcomes and employability, strengthening our reputation within the medical community. We advanced AI-enabled enhancements to Afya Whitebook, iClinic and ReceitaPro further supporting clinical productivity and evidence-based decision-making at the point of care. In parallel, we launched Instituto Afya, aligned with the UN 2030 Agenda to address chronic disease challenges. Together, these initiatives strengthen our ecosystem and support long-term value creation. During October, we took coordinated actions to strengthen our capital structure. We issued commercial notes totaling R$1.5 billion in two series, maturing in 2028 and 2030, with interest rates of CDI+0.70% and CDI+0.85% per year, respectively. Using the proceeds, we repurchased all 150,000 Series A perpetual convertible preferred shares from SoftBank for R$831.6 million and fully repaid R$500 million related to Afya Participacoes first debenture issuance. These actions extend debt duration, and reinforce our disciplined approach to capital management. Looking ahead, we remain confident in our ability to keep delivering sustainable growth. Our integrated ecosystem, operational excellence and innovation agenda position Afya to execute with quality and consistency. We reaffirm our 2025 guidance and are proud of the progress achieved so far – energized by the opportunities ahead as we continue to transform the medical journey and physician career success in Brazil.”